Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company in the world.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 584.52% and ...

With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

All of this sounds fantastic and could make Lilly an excellent buy, but before you take action, consider this warning: This ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...

Companies usually only issue stock splits after extended periods of strong returns, and a stock split is a sign a company's ...

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.

Eli Lilly (LLY) Stock Price Prediction in 2025 The current Wall Street consensus 1-year price target of Eli Lilly stock is $1030.00, which is 13.06% higher than today’s price of $911.05.